Printer Friendly

CooperGenomics Receives ISO 15189 Accreditation in United Kingdom Laboratories for Noninvasive Prenatal Testing.

M2 PHARMA-March 9, 2017-CooperGenomics Receives ISO 15189 Accreditation in United Kingdom Laboratories for Noninvasive Prenatal Testing

(C)2017 M2 COMMUNICATIONS

- US-based prenatal testing specialist CooperGenomics has received ISO 15189 accreditation for both its London and Nottingham-based laboratories, the company said.

Issued by the United Kingdom Accreditation Services, this certification validates the quality and accuracy of the genetic testing services provided by the laboratories.

The accreditation includes all noninvasive prenatal testing, preimplantation genetic diagnosis, and preimplantation genetic screening services provided in the CooperGenomics London and Nottingham facilities. CooperGenomics is the first laboratory in the United Kingdom to receive such accreditation for NIPT and PGS services.

CooperGenomics is part of CooperSurgical, which offers products and services for women's health, fertility and genetic testing.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Geographic Code:4EUUK
Date:Mar 9, 2017
Words:132
Previous Article:Innovus Pharma Receives CPNP Notification to Commercialize Sensum+ in the European Union.
Next Article:BerGenBio ASA and Merck & Co. partner for phase II combination lung cancer trials.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters